# Candesant Biomedical

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/candesant-biomedical

- Industry: Medical Devices & Equipment
- Headquarters: San Francisco, US
- Website: www.candesant.com
- Total disclosed funding: $35M
- Latest round: Series B (Apr 12, 2022)
- Investors on record: 4

## About

Based in California, US, and founded in 2016 by its CEO Niquette Hunt, and co-founder Jacob Waugh, Candesant Biomedical, Inc. operates as a clinical-stage company that develops and commercializes non-invasive treatments for excessive sweating or hyperhidrosis. In April 2022, Candesant Biomedical, Inc. raised USD 35.36 million in series B funding led by KCK Group, with participation from Astia Angels, Correlation Ventures, and Polaris Partners. 

Candesant Biomedical, Inc. provides SweatTech, a non-toxic, non-invasive, and non-staining technology called Targeted Alkali Thermolysis (TAT) that provides a solution to excessive sweating. The company's Targeted Alkali Thermolysis (TAT) offers bi-layer patch that enables precise delivery of heat to target the sweat glands. It leverages the interaction between alkali metals and water to reduced sweating.

## Funding rounds

- Series B, Apr 12, 2022, $35M — Polaris Partners, Correlation Ventures, Astia Angels, KCK Group

## Investors

- Polaris Partners (https://capitalatlas.ai/funds/polaris-partners) — Series B
- Correlation Ventures (https://capitalatlas.ai/funds/correlation-ventures) — Series B
- Astia Angels (https://capitalatlas.ai/funds/astia-angels) — Series B
- KCK Group — Series B